BeyondSpring Files 2020 Annual Report on Form 20-F

Rhea-AI Summary

BeyondSpring, a biopharmaceutical company, filed its annual report on Form 20-F for the fiscal year ended December 31, 2020, with the SEC on April 30, 2021. The report includes audited financial statements and is accessible via the SEC's website and BeyondSpring's site under the Investors section. BeyondSpring focuses on developing innovative cancer therapies, primarily its lead asset plinabulin, aimed at preventing chemotherapy-induced neutropenia and studying its effects in non-small cell lung cancer. Shareholders can request a hard copy of the report free of charge.

Positive

• Filed annual report on Form 20-F with audited financial statements.
• Focus on innovative cancer therapies, particularly plinabulin.
• Plinabulin is filed for approval in the U.S. and China for chemotherapy-induced neutropenia.
• Ongoing pivotal study for anti-cancer benefit in non-small cell lung cancer.

Negative

• None.

NEW YORK, April 30, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2020 with the U.S. Securities and Exchange Commission (“SEC”) on April 30, 2021. The annual report on Form 20-F, which contains the Company’s audited consolidated financial statements, can be accessed on the SEC’s website at www.sec.gov and on the Company’s website at www.beyondspringpharma.com under “Financials & Filings” in the Investors section.

The Company will provide a hard copy of its annual report containing its audited consolidated financial statements, free of charge, to its shareholders upon request. Requests should be directed to Investor Relations, BeyondSpring Inc., 28 Liberty Street, 39th Floor, New York, NY 10005 USA.

About BeyondSpring

Headquartered in New York City, BeyondSpring is a global biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to improve clinical outcomes for patients who have high unmet medical needs. BeyondSpring’s first-in-class lead asset plinabulin is a “pipeline in a drug.” It is filed for approval in the U.S. and China for the prevention of chemotherapy-induced neutropenia (CIN) and has a fully enrolled pivotal study to test an anti-cancer benefit with an overall survival primary endpoint in non-small cell lung cancer (NSCLC). Additionally, it is being broadly studied in combination with various immuno-oncology agents that could boost the effects of PD-1 / PD-L1 antibodies. In addition to plinabulin, BeyondSpring’s extensive pipeline includes three pre-clinical immuno-oncology assets and a subsidiary, SEED Therapeutics, which is leveraging a proprietary targeted protein degradation drug discovery platform.

Investor Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
+1 617-430-7577
arr@lifesciadvisors.com

Media Contact:
Darren Opland, Ph.D.
LifeSci Communications
+1 646-627-8387
darren@lifescicomms.com

FAQ

When did BeyondSpring file its annual report?

BeyondSpring filed its annual report on Form 20-F on April 30, 2021.

What is the significance of the Form 20-F for BeyondSpring?

Form 20-F includes audited consolidated financial statements and provides transparency to investors.

What is plinabulin's role in BeyondSpring's pipeline?

Plinabulin is BeyondSpring's lead asset focused on preventing chemotherapy-induced neutropenia and testing its anti-cancer effects.

How can shareholders access BeyondSpring's annual report?

Shareholders can access the annual report on the SEC's website or request a hard copy from Investor Relations.

What is BeyondSpring's focus in cancer treatment?

BeyondSpring focuses on developing innovative immuno-oncology therapies to improve clinical outcomes for cancer patients.